Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 4/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.47 |
| ▸ | CCR5 | P51681 | 4/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | WDR91 | A4D1P6 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6412861 | 0.99 | UTS2R (0.51) | UTS2RROCK2ROCK1CCR5ACE2 | |
| SCHEMBL6413738 | 0.95 | UTS2R (0.55) | UTS2RROCK2ROCK1CCR5HDAC1 | |
| Hydrochloric Acid SCHEMBL6409140 | 0.94 | UTS2R (0.55) | UTS2RROCK2ROCK1CCR5HDAC1 | |
| SCHEMBL6411896 | 0.94 | ROCK1 (0.54) | UTS2RROCK2ROCK1CCR5HDAC1 | |
| Hydrochloric Acid SCHEMBL6414705 | 0.93 | ROCK1 (0.54) | UTS2RROCK2ROCK1CCR5HDAC1 | |
| SCHEMBL6416471 | 0.93 | UTS2R (0.49) | UTS2RROCK2ROCK1CCR5WDR91 | |
| SCHEMBL6408926 | 0.93 | UTS2R (0.49) | UTS2RROCK2ROCK1CCR5ACE2 | |
| SCHEMBL6416612 | 0.92 | ROCK2 (0.47) | UTS2RROCK2ROCK1CCR5HDAC1 | |
| Hydrochloric Acid SCHEMBL6415367 | 0.92 | UTS2R (0.48) | UTS2RROCK2ROCK1CCR5ACE2 | |
| Hydrochloric Acid SCHEMBL6409279 | 0.92 | UTS2R (0.48) | UTS2RROCK2ROCK1CCR5WDR91 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA INC (CA) | 2005-04-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | CXCR1, CXCR4, CXCR2 | UTS2R 126/4885ROCK2 1735/4885ROCK1 1002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.